Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin

Liver Transplantation

Volumn 17, Issue 11, 2011, Pages 1318-1327

  Giusto, Michela ^a   Rodriguez, Maria ^a   Navarro, Laia ^a   Rubin, Angel ^a,b   Aguilera, Victoria ^a,b   San Juan, Fernando ^a   Ortiz, Cecilia ^a,b   López Andujar, Rafael ^a   Prieto, Martín ^a,b   Berenguer, Marina ^a,b,c  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON; RIBAVIRIN; TACROLIMUS;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ARTICLE; BODY MASS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE ASSOCIATION; FEMALE; FIBROSIS; GENOTYPE; GRAFT RECIPIENT; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIREMIA;

ADULT; AGED; ANEMIA; ANTIVIRAL AGENTS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; PREVALENCE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 82955197327     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22387     Document Type: Article

References (30)

1. Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl 2006;12: 1192-1204. (Pubitemid 44194586)
2. Samuel D, Forns X, Berenguer M, Trautwein C, Burroughs A, Rizzetto M, Trepo C. Report of the monothe-matic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol 2006;45:127-143. (Pubitemid 43850627)
3. Carrión JA, Navasa M, García-Retortillo M, García-Pagan JC, Crespo G, Bruguera M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007;132:1746-1756. (Pubitemid 46695723)
4. Picciotto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo GG, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007;46:459-465. (Pubitemid 46185706)
5. Berenguer M, Palau A, Aguilera V, Rayón JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008;8:679-687. (Pubitemid 351287553)
6. Selzner N, Renner EL, Selzner M, Adeyi O, Kashfi A, Therapondos G, et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation 2009; 88:1214-1221.
7. Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Kremers WK, et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant 2008;8:2426-2433.
8. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008;49: 274-287.
9. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006;6: 1586-1599. (Pubitemid 43945798)
10. Gurusamy KS, Tsochatzis E, Xirouchakis E, Burroughs AK, Davidson BR. Antiviral therapy for recurrent liver graft infection with hepatitis C virus. Cochrane Database Syst Rev 2010:CD006803.
11. Saab S, Oh MK, Ibrahim AB, Durazo F, Han S, Yersiz H, et al. Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C. Liver Transpl 2007;13:1032-1038. (Pubitemid 47177137)
12. McHutchison JG, Manns MP, Longo DL. Definition and management of anemia in patients infected with hepatitis C virus. Liver Int 2006;26:389-398.
13. Dan AA, Martin LM, Crone C, Ong JP, Farmer DW, Wise T, et al. Depression, anemia and health-related quality of life in chronic hepatitis C. J Hepatol 2006;44:491-498. (Pubitemid 43227873)
14. McHutchison JG, Manns MP, Brown RS Jr, Reddy KR, Shiffman ML, Wong JB. Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am J Gastroenterol 2007;102:880-889. (Pubitemid 46496635)
15. Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Kubo M, et al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy - a genome-wide study of Japanese HCV virus patients. Gastroenterology 2010;139:1190-1197.
16. Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010;464:405-408.
17. Sulkowski MS, Shiffman ML, Afdhal NH, Reddy KR, McCone J, Lee WM, et al.; for IDEAL Study Team. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterol-ogy 2010;139:1602-1611.
18. Charlton MR, Wall WJ, Ojo AO, Ginès P, Textor S, Shi-hab FS, et al.; for International Liver Transplantation Society Expert Panel. Report of the first International Liver Transplantation Society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl 2009;15:S1-S34.
19. Brochot E, Castelain S, Duverlie G, Capron D, Nguyen-Khac E, François C. Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy. Antivir Ther 2010;15:687-695.
20. Bertino G, Ardiri A, Boemi PM, Calvagno GS, Ruggeri IM, Speranza A, et al. Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis. Eur J Clin Pharmacol 2010;66:1055-1063.
21. Sherman M, Cohen L, Cooper MA, Elkashab M, Feinman V, Fletcher D, et al. Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin. Can J Gastroenterol 2006;20:479-485. (Pubitemid 44227466)
22. Collantes RS, Younossi ZM. The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin. J Clin Gastroenterol 2005;39(suppl): S9-S13. (Pubitemid 40024232)
23. Mulhall BP, Younossi Z. Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C. J Clin Gastroenterol 2005;39(suppl):S23-S27. (Pubitemid 40024234)
24. Moore EM, Bellomo R, Nichol AD. Erythropoietin as a novel brain and kidney protective agent. Anaesth Intensive Care 2011;39:356-372.
25. Wade JR, Snoeck E, Duff F, Lamb M, Jorga K. Pharma-cokinetics of ribavirin in patients with hepatitis C virus. Br J Clin Pharmacol 2006;62:710-714. (Pubitemid 44749548)
26. Jain AB, Eghtesad B, Venkataramanan R, Fontes PA, Kashyap R, Dvorchik I, et al. Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection. Liver Transpl 2002;8:1007-1013. (Pubitemid 35363626)
27. Balan V, Schwartz D, Wu GY, Muir AJ, Ghalib R, Jackson J, et al.; for HCV Natural History Study Group. Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/riba-virin. Am J Gastroenterol 2005;100:299-307. (Pubitemid 40314513)
28. Bardet V, Junior AP, Coste J, Lecoq-Lafon C, Chouze-noux S, Bernard D, et al. Impaired erythropoietin production in liver transplant recipients: the role of calcineurin inhibitors. Liver Transpl 2006;12: 1649-1654. (Pubitemid 44742544)
29. Hodo Y, Tsuji K, Mizukoshi E, Yamashita T, Sakai A, Nakamoto Y, et al. Pure red cell aplasia associated with concomitant use of mycophenolate mofetil and ribavirin in post-transplant recurrent hepatitis C. Transpl Int 2006;19:170-171.
30. Berenguer M, Aguilera V, Prieto M, Ortiz C, Rodríguez M, Gentili F, et al. Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. Liver Transpl 2009;15:738-746.